Keyphrases
25(OH)D Level
100%
Resectable Pancreatic Cancer
100%
25-hydroxyvitamin D Levels
100%
Overall Survival
57%
Gemcitabine
42%
Vitamin D Deficiency
42%
Vitamin D Status
28%
Non-associated
28%
Black Men
28%
White Patients
28%
25-hydroxyvitamin D (25OHD)
28%
Chemotherapy
14%
Randomized Trial
14%
Cell Line Models
14%
Placebo
14%
Progression-free Survival
14%
Pancreatic Tumor
14%
New Diagnosis
14%
Vitamin D Metabolism
14%
Tumor Behavior
14%
Serum 25-hydroxyvitamin D [25(OH)D]
14%
Bevacizumab
14%
Statistical Test
14%
Rank Score Test
14%
Medicine and Dentistry
25 Hydroxyvitamin D
100%
Pancreas Cancer
100%
Overall Survival
80%
Gemcitabine
60%
Vitamin D
60%
Vitamin D Deficiency
40%
Hypovitaminosis D
40%
Progression Free Survival
20%
Chemotherapy
20%
Malignant Neoplasm
20%
Pancreas Tumor
20%
Vitamin D Metabolism
20%
Placebo
20%
Cell Line
20%
Bevacizumab
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Cancer
100%
25 Hydroxyvitamin D
100%
Overall Survival
80%
Vitamin D
80%
Gemcitabine
60%
Vitamin D Deficiency
40%
Hypovitaminosis D
40%
Chemotherapy
20%
Malignant Neoplasm
20%
Placebo
20%
Progression Free Survival
20%
Pancreas Tumor
20%
Bevacizumab
20%
Biochemistry, Genetics and Molecular Biology
Overall Survival
100%
Vitamin D
75%
Gemcitabine
75%
Hypovitaminosis D
50%
Statistical Test
25%
Progression Free Survival
25%
Vitamin D Metabolism
25%
Bevacizumab
25%